---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-003754"
form_type: "8-K"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:41:07.222174+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences shareholders approve reverse stock split at ratio up to 1:40

## Summary
- Reverse split ratio range of 1-for-10 to 1-for-40, board discretion, must occur before June 30, 2023.
- Proposal passed with 9,730,160,440 FOR vs 1,678,239,563 AGAINST; no broker non-votes.
- Adjournment proposal also approved with 9,995,797,812 FOR.
- Special meeting held Feb 15, 2023; record date Dec 30, 2022 with 24,642,960 common shares outstanding.

## SEC filing metadata
- accession: 0000950170-23-003754
- form_type: 8-K
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017023003754/0000950170-23-003754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017023003754/rkda-20230215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-003754
- JSON: https://secwatch.observer/filing/0000950170-23-003754.json
- Plain text: https://secwatch.observer/filing/0000950170-23-003754.txt

## Key facts
- Shareholder Votes
  Arcadia Biosciences, Inc. shareholders approved To approve an amendment to the Company’s amended and restated certificate of incorporation to effect, at the discretion of the Company’s Board of Directors (“Board”) but prior to June 30, 2023, a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-fo at the 2023-02-15 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-02-15
  source text: 1. To approve an amendment to the Company’s amended and restated certificate of incorporation to effect, at the discretion of the Company’s Board of Directors (“Board”) but prior to June 30, 2023, a reverse stock split of all of the outstanding shares of our Common Stock at a ratio in the range of 1-for-10 to 1-for-40, with such ratio to be determined by the Board in its discretion (“Reverse Stock Split Proposal”). FOR AGAINST ABSTAIN Broker Non-Votes 9,730,160,440 1,678,239,563 229,293,064 --
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017023003754/0000950170-23-003754-index.htm
- Shareholder Votes
  Arcadia Biosciences, Inc. shareholders approved To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal. at the 2023-02-15 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-02-15
  source text: 2. To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal. FOR AGAINST ABSTAIN Broker Non-Votes 9,995,797,812 1,260,616,357 381,278,898 --
  evidence_url: https://www.sec.gov/Archives/edgar/data/1469443/000095017023003754/0000950170-23-003754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.